Top

12-07-2016 | Osteoporosis | Book Chapter | Article

12. Medical Treatment of Age Related Osteoporosis

Authors: Eric Kai-Chung Wong, BSc, MD, Lisa Ha-Yeon Kim, BHSc, MD, Alexandra Papaioannou, BScN, MD, MSc, FRCP(C), FACP

Publisher: Springer International Publishing

Abstract

Osteoporosis risk and complications increase with age. The syndrome of osteoporosis of old age is different from postmenopausal osteoporosis because both men and women are affected as they age. The aim of osteoporosis treatment is to prevent fractures by preventing falls and strengthening the skeleton. Bone mineral density (BMD) is used as a guide to predict future fracture risk. Numerous clinical trials have tested the efficacy of both nutritional supplements (calcium and vitamin D) and pharmacologic therapies to reduce fracture risk in those with osteoporosis. However, not all trials included patients who were very old, despite the fact that they are at increased risk of fractures. Trials also sometimes demonstrated efficacy in preventing only certain types of fractures but not others. This chapter reviews the evidence supporting osteoporosis treatments.

Lips P. Vitamin D, deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477–501. doi:10.1210/edrv.22.4.0437.CrossRefPubMed

Kalyani RR, Stein B, Valiyil R, Manno R, Maynard JW, Crews DC. Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis. J Am Geriatr Soc. 2010;58:1299–310. doi:10.1111/j.1532-5415.2010.02949.x.CrossRefPubMedPubMedCentral

Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42. doi:10.1038/nature01658.CrossRefPubMed

William J. Boyle WSS& DLL. Osteoclast differentiation and activation. Clin Calcium. 2007;17:484–92. doi:10.1038/nature01658.

Chitre M, Shechter D, Grauer A. Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2011;68:1409–18. doi:10.2146/ajhp100493.CrossRefPubMed

Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009;5:20–7. doi:10.1038/ncprheum1027.CrossRefPubMed

Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7:255–61.CrossRefPubMed

Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20:2097–104. doi:10.1359/JBMR.050814.CrossRefPubMed

Rabenda V, Bruyère O, Reginster J-Y. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int. 2011;22:893–901. doi:10.1007/s00198-010-1469-x.CrossRefPubMed

10.

Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, et al. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:1627–34. doi:10.1002/jbmr.1644.CrossRefPubMed

11.

Austin M, Yang Y-C, Vittinghoff E, Adami S, Boonen S, Bauer DC, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27:687–93. doi:10.1002/jbmr.1472.CrossRefPubMedPubMedCentral

12.

Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:38–42. doi:10.1007/s00198-003-1490-4.CrossRefPubMed

13.

Shuid AN, Khaithir TMN, Mokhtar SA, Mohamed IN. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag. 2014;106:937. doi:10.2147/TCRM.S72456.CrossRef

14.

Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004;52:1832–9. doi:10.1111/j.1532-5415.2004.52506.x.CrossRefPubMed

15.

Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, Törring O, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96. doi:10.1210/jc.2010-2784.

16.

Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest. 1982;70:716–23.CrossRefPubMedPubMedCentral

17.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604–10. doi:10.1056/NEJM200008313430902.CrossRefPubMed

18.

Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216–26. doi:10.1056/NEJMoa035725.CrossRefPubMed

19.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25:2239–50. doi:10.1002/jbmr.119.CrossRefPubMed

20.

Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357:266–81. doi:10.1056/NEJMra070553.CrossRefPubMed

21.

Bischoff-Ferrari HA, Willett WC, Orav EJ, Oray EJ, Lips P, Meunier PJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367:40–9. doi:10.1056/NEJMoa1109617.CrossRefPubMed

22.

Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303:1815–22. doi:10.1001/jama.2010.594.CrossRefPubMed

23.

Rizzoli R, Boonen S, Brandi M-L, Bruyère O, Cooper C, Kanis JA, et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin. 2013;29:305–13. doi:10.1185/03007995.2013.766162.CrossRefPubMed

24.

Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:827–38. doi:10.7326/0003-4819-155-12-201112200-00005.CrossRefPubMed

25.

Bauer DC. Clinical practice. Calcium supplements and fracture prevention. N Engl J Med. 2013;369:1537–43. doi:10.1056/NEJMcp1210380.CrossRefPubMedPubMedCentral

26.

Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–83. doi:10.1056/NEJMoa055218.CrossRefPubMed

27.

Reid IR. Osteoporosis treatment: focus on safety. Eur J Intern Med. 2013;24:691–7. doi:10.1016/j.ejim.2013.03.012.CrossRefPubMed

28.

Lewis JR, Radavelli-Bagatini S, Rejnmark L, Chen JS, Simpson JM, Lappe JM, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res. 2015;30:165–75. doi:10.1002/jbmr.2311.CrossRefPubMed

29.

Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s health initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.CrossRefPubMedPubMedCentral

30.

Manson JE, Allison MA, Carr JJ, Langer RD, Cochrane BB, Hendrix SL, et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative. Menopause. 2010;17:683–91. doi:10.1097/gme.0b013e3181d683b5.PubMedPubMedCentral

31.

Wang TKM, Bolland MJ, van Pelt NC, Horne AM, Mason BH, Ames RW, et al. Relationships between vascular calcification, calcium metabolism, bone density, and fractures. J Bone Miner Res. 2010;25:2777–85. doi:10.1002/jbmr.183.CrossRefPubMed

32.

Castelo-Branco C, Cortés X, Ferrer M. Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric. 2010;13:578–84. doi:10.3109/13697130903452804.CrossRefPubMed

33.

Lips P, Bouillon R, van Schoor NM, Vanderschueren D, Verschueren S, Kuchuk N, et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf). 2010;73:277–85. doi:10.1111/j.1365-2265.2009.03701.x.CrossRef

34.

Aloia JF. Clinical review: the 2011 report on dietary reference intake for vitamin D: where do we go from here? J Clin Endocrinol Metab. 2011;96:2987–96. doi:10.1210/jc.2011-0090.CrossRefPubMed

35.

Gallagher JC, Sai A, Templin T, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med. 2012;156:425–37. doi:10.7326/0003-4819-156-6-201203200-00005.CrossRefPubMed

36.

Lewis JR, Zhu K, Prince RL. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J Bone Miner Res. 2012;27:719–22. doi:10.1002/jbmr.1484.CrossRefPubMed

37.

Manson JE, Bassuk SS. Calcium supplements: do they help or harm? Menopause. 2014;21:106–8. doi:10.1097/GME.0b013e31829be090.CrossRefPubMed

38.

Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.CrossRefPubMedPubMedCentral

39.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22. doi:10.1056/NEJMoa067312.CrossRefPubMed

40.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–41.CrossRefPubMed

41.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333–40. doi:10.1056/NEJM200102013440503.CrossRefPubMed

42.

Sato Y, Kanoko T, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med. 2005;165:1737–42. doi:10.1001/archinte.165.15.1737.CrossRefPubMed

43.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202–11. doi:10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W.CrossRefPubMed

44.

Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493–501. doi:10.1016/S0025-6196(11)61093-8.CrossRefPubMed

45.

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–22. doi:10.4065/81.8.1013.CrossRefPubMed

46.

Namasivayam AM, Steele CM. Malnutrition and Dysphagia in long-term care: a systematic review. J Nutr Gerontol Geriatr. 2015;34:1–21. doi:10.1080/21551197.2014.1002656.CrossRefPubMed

47.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–82. doi:10.1001/jama.280.24.2077.CrossRefPubMed

48.

Masud T, McClung M, Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging. 2009;4:445–9. doi:10.2147/CIA.S8200.CrossRefPubMedPubMedCentral

49.

Serrano AJ, Begona L, Anitua E, Cobos R, Orive G. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol. 2013;29:1005–14. doi:10.3109/09513590.2013.813468.CrossRefPubMed

50.

Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9. doi:10.1359/JBMR.040325.CrossRefPubMed

51.

McCloskey EV, Beneton M, Charlesworth D, Kayan K, DeTakats D, Dey A, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007;22:135–41. doi:10.1359/jbmr.061008.CrossRefPubMed

52.

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809. doi:10.1056/NEJMoa074941.CrossRefPubMed

53.

Prieto-Alhambra D, Judge A, Arden NK, Cooper C, Lyles KW, Javaid MK. Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial. Osteoporos Int. 2014;25:77–83. doi:10.1007/s00198-013-2420-8.CrossRefPubMed

54.

Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011;96:1006–14. doi:10.1210/jc.2010-2730.CrossRefPubMed

55.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83–91. 00110083.198 [pii].CrossRefPubMed

56.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–52. doi:10.1001/jama.282.14.1344.CrossRefPubMed

57.

Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22:741–53. doi:10.1007/s00198-010-1335-x.CrossRefPubMed

58.

Rackoff P. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Clin Interv Aging. 2009;4:207–14. doi:10.1016/j.bone.2007.09.001.CrossRefPubMedPubMedCentral

59.

Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103–11. doi:10.1007/s00223-002-2011-8.CrossRefPubMed

60.

Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12:1–12.

61.

Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60:324–33.PubMedPubMedCentral

62.

Khan AA, Rios LP, Sándor GKB, Khan N, Peters E, Rahman MO, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol. 2011;38:1396–402. doi:10.3899/jrheum.100221.CrossRefPubMed

63.

Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27:2544–50. doi:10.1002/jbmr.1719.CrossRefPubMed

64.

Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290:1729–38. doi:10.1001/jama.290.13.1729.CrossRefPubMed

65.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33. doi:10.1001/jama.288.3.321.CrossRefPubMed

66.

Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:524–8. doi:10.1210/er.2001-4002.CrossRefPubMed

67.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–45. joc90496 [pii].CrossRefPubMed

68.

Silverman SL, Chines AA, Kendler DL, Kung AWC, Teglbjærg CS, Felsenberg D, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int. 2012;23:351–63. doi:10.1007/s00198-011-1691-1.CrossRefPubMed

69.

Palacios S, Silverman SL, de Villiers TJ, Levine AB, Goemaere S, Brown JP, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis. Menopause. 2015;22:806–13. doi:10.1097/GME.0000000000000419.CrossRefPubMed

70.

Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686–96. doi:10.1056/NEJMoa0808692.CrossRefPubMed

71.

Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:1687–95. doi:10.1002/art.23461.CrossRefPubMed

72.

Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res. 2006;21:1113–20. doi:10.1359/jbmr.060404.CrossRefPubMed

73.

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816–22. doi:10.1210/jc.2004-1774.CrossRefPubMed

74.

CHMP. Protelos and Osseor Article-20 procedure: CHMP scientific conclusions and PRAC assessment report. Eur Med Agency. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Protelos_and_Osseor/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500162132.pdf. Accessed 15 Feb 2015.

75.

European Medicines Agency. Protelos-H-C-560-PSU-31: EPAR—Assessment Report—Periodic safety update report. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdf.

76.

European Medicines Agency. Protelos-H-C-560-A20–34: EPAR—Assessment Report—Article 20. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500131789.pdf.

77.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65. doi:10.1056/NEJMoa0809493.CrossRefPubMed

78.

Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwiński E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98:4483–92. doi:10.1210/jc.2013-1597.CrossRefPubMedPubMedCentral

79.

Papapoulos S, Roux C, Bone HG, Dakin P, Czerwinski E, Frey D, Kendler D, Lewiecki EM, Malouf J, Mellstrom D, Reginster JY, Resche H, Daizadeh NS, Wang A, Gavin M, Wagman RB, Brandi M. Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the FREEDOM extension study. Osteoporos Int. 2015;26:S37–9.CrossRef

80.

Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–61. doi:10.1359/jbmr.080901.CrossRefPubMed

81.

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81. doi:10.1359/jbmr.090716.CrossRefPubMed

82.

Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis. Osteoporos Int. 2014;25:1953–61. doi:10.1007/s00198-014-2692-7.PubMed

83.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy. 2013;11:485–97. doi:10.1007/s40258-013-0047-8.CrossRefPubMed

84.

Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ. 2012;15 Suppl 1:3–14. doi:10.3111/13696998.2012.737393.CrossRefPubMed

85.

Ström O, Jönsson B, Kanis JA. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis. Osteoporos Int. 2013;24:1491–502. doi:10.1007/s00198-012-2115-6.CrossRefPubMed

86.

Lexicomp. Lexicomp drug database. 2015. http://www.wolterskluwercdi.com/lexicomp-online/.

87.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41. doi:10.1056/NEJM200105103441904.CrossRefPubMed

88.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc. 2006;54:782–9. doi:10.1111/j.1532-5415.2006.00695.x.CrossRefPubMed

89.

Sikon A, Batur P. Profile of teriparatide in the management of postmenopausal osteoporosis. Int J Womens Health. 2010;2:37–44. doi:10.2147/IJWH.S4919.CrossRefPubMedPubMedCentral

90.

Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res. 2007;22:334. doi:10.1359/jbmr.061111.CrossRefPubMed

91.

Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int. 2006;17:273–80. doi:10.1007/s00198-005-2013-2.CrossRefPubMed

92.

Nevitt MC, Chen P, Kiel DP, Reginster JY, Dore RK, Zanchetta JR, et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int. 2006;17:1630–7. doi:10.1007/s00198-006-0177-z.CrossRefPubMed

93.

Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93:852–60. doi:10.1210/jc.2007-0711.CrossRefPubMed

94.

Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207–15. doi:10.1097/01.OGX.0000115856.54444.D6.CrossRefPubMed

95.

Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382:50–6. doi:10.1016/S0140-6736(13)60856-9.CrossRefPubMedPubMedCentral

96.

Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353:555–65. doi:10.1097/01.ogx.0000193859.78235.fe.CrossRefPubMed

97.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028–39. doi:10.1097/01.ogx.0000310357.43258.f1.CrossRefPubMed

98.

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial. Ann Intern Med. 2007;146:326–39.CrossRefPubMed

99.

Appelman-Dijkstra NM, Papapoulos SE. Novel approaches to the treatment of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2014;28:843–57. doi:10.1016/j.beem.2014.07.003.CrossRefPubMed

100.

Papapoulos SE. Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis. Nat Rev Endocrinol. 2015;11:69–70. doi:10.1038/nrendo.2014.214.CrossRefPubMed

Medicine Matters Rheumatology

Abstract